“Emicizumab was shown to bind similarly to the corresponding cynomolgus monkey coagulation factors, as such the cynomolgus monkey is a pharmacologically relevant species.”
✓ VerifiedFDA multi-discipline review, p. 25Source ↗
Why that species
Binds/activates cynomolgus FIX/FX comparably to human; no FX activation with mouse or rat factors
“In an enzyme assay using purified Cynomolgus monkey, rat and mouse FIXa and FX, emicizumab was found to cross-react only with the corresponding clotting factors of Cynomolgus monkeys.”
No surrogate; clinical molecule tested in monkey (FVIII-neutralizing antibodies used only to create hemophilia models)
“Emicizumab was generally well tolerated in a 26-week toxicology study conducted in cynomolgus monkeys administered weekly SC doses of emicizumab at 1, 6, and 30 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 26Source ↗
Species: general tox
Cynomolgus monkey only
“Emicizumab was generally well tolerated in a 26-week toxicology study conducted in cynomolgus monkeys administered weekly SC doses of emicizumab at 1, 6, and 30 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 26Source ↗
Species: DART
Not conducted (hemophilia A is X-linked recessive)
“Animal reproductive and developmental toxicology studies were not conducted with emicizumab as hemophilia A is inherited in an X-linked recessive manner.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: carcinogenicity
Not conducted (no pharmacologically relevant rodent species)
“Carcinogenicity studies were not conducted due to lack of a pharmacologically relevant rodent species.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Surrogate used in
No surrogate used; clinical molecule tested in cynomolgus monkey
“Emicizumab was shown to bind similarly to the corresponding cynomolgus monkey coagulation factors, as such the cynomolgus monkey is a pharmacologically relevant species.”
✓ VerifiedFDA multi-discipline review, p. 25Source ↗